Kepler Vision Technologies La​unches New Computer Vision Solution For Elderly Care

March 10, 2021

Kepler Vision Technologies today announced the launch of its Kepler Night Nurse Edge Box.

Designed to process Kepler Vision’s Night Nurse (KNN) software, this new device uses computer vision technology to increase the safety of patients at night, and allow care workers to focus on providing better quality care.

Through the use of deep learning and computer vision, KNN is able to detect both falls and when patients are in physical distress, automatically alerting staff when they need assistance. Replacing old sensor systems such as bed mats, motion sensors and other sensor devices, including necklaces and bracelets, the software allows staff to immediately respond to patients and eliminate 99% of false alarms.

Once the Night Nurse Edge Box’s initial three-month calibration phase is complete, video feeds of patients no longer leave the premises of the care facility, giving both patients and staff a feeling of greater privacy. After this three-month period, live video feeds are analyzed in the Edge Box without ever being seen by any human being. The only outputs from the Edge Box are text alerts to staff that is sent when patients need help. This removes concerns around having video cameras monitoring patients, while still enabling staff to instantly respond when something is wrong. Furthermore, the solution frees up staff to engage in other work that would otherwise be wasted.

Dr. Harro Stokman, CEO of Kepler Vision Technologies, said: “We are incredibly excited about the new functionality and flexibility that the Kepler Night Nurse Edge Box provides in looking after the wellbeing of patients at night. This new product combines the proven effectiveness of our Night Nurse solution with reduced setup cost and complexity and removes the need for a constant high-speed internet connection processing many feeds at once. Given the current state of the care home industry, we are proud to be offering something that reduces the strain on staff by allowing them to more effectively administer care, without sacrificing the privacy of patients.”

Uniquely among computer vision video processing solutions, Kepler Night Nurse can analyze fisheye lensed video feeds without “straightening” the images – something with which human operators have great difficulty. In addition, running the video processing locally on the Edge Box instead of running it in the cloud eliminates the need to compress video streams. This allows for more close-up inspection of what is going on in the video, providing increased accuracy and reliability of the computer vision software.

Beyond simply alerting care staff to a patient in need, Kepler’s Night Nurse solution can be customized by the caretakers to identify different causes for concern across their patients. For example, if a patient is having trouble standing up, or is spending an unusual amount of time in the bathroom, the software offers self-service functionality for staff to send alerts fitting the specific needs of the patient. In addition, the KNN reporting can automatically add accurate behavioral observations to a patient’s medical file which can help doctors with long-term patient monitoring – identifying behavioral patterns that may indicate a change in wellbeing.

Kepler Vision’s Night Nurse solution is the world’s first computer vision-based fall detector to be awarded medical device status. Its computer vision-powered software officially registered as a medical device in compliance with the European council directive 93/42/EEC. The registration signifies that the software has been tested both internally and, in the field, to meet the highest specifications and that risk assessment and mitigating measures have been met. The software encodes seventeen patent applications of which three have been granted, with a further 15 pending.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version